Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...
In the latest trading session, Eli Lilly (LLY) closed at $1,056.88, marking a +1.45% move from the previous day. This move outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow saw an upswing ...
Lily Allen returned to the Saturday Night Live stage after nearly 19 years away with two performances from her latest pop album, West End Girl. Allen, an SNL musical guest in early 2007, opened with ...
Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...
The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...
Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s (NYSE: LLY) experimental oral ...
We may receive a commission on purchases made from links. Winter is here, and snow and colder temperatures have arrived. Winter weather means we're tracking snow, ice, and slush into our cars, which ...
The actress offered exclusive photographs of herself in exchange for donations Desiree Anello is a Writer/Reporter at PEOPLE. She has been working at PEOPLE since 2025. Her work has previously ...
Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss ...
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the ...